Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of ~40,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide.
Our global portfolio includes best-in-class, iconic brand name products as well as global key brands; generics, including branded and complex generics; biosimilars; and over-the-counter offerings across a wide range of therapeutic areas. We are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (insulin glargine injection), 100 units/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022